Navigation Links
A new treatment for kidney disease-associated heart failure?
Date:1/9/2013

Chronic kidney disease (CKD) patients frequently suffer from mineral bone disorder, which causes vascular calcification and, eventually, chronic heart failure. Similar to patients with CKD, mice with low levels of the protein klotho (klotho hypomorphic mice) also develop vascular calcification and have shorter life spans compared to normal mice. In this issue of the Journal of Clinical Investigation, Florian Lang and colleagues at the University of Tbingen in Germany, found that treatment with the mineralocorticoid receptor antagonist spironolactone reduced vascular calcification in klotho hypomorphic mice and increased their life span. In a companion Attending Physician article, Darryl Quarles of the University of Tennessee discusses the implications of these findings for the treatment of CKD patients.

TITLE:
Spironolactone-sensitive vascular calcification and Pit-1-dependent osteoblastic differentiation in klotho-hypomorphic mice

AUTHOR CONTACT:
Florian Lang
Dept. of Physiology, Tuebingen, NULL, DEU
Phone: +4970712972194; Fax: +497071295618; E-mail: florian.lang@uni-tuebingen.de

View this article at: http://www.jci.org/articles/view/64093?key=3010c850d2f970ad6617

ACCOMPANYING THE ATTENDING PHYSICIAN

TITLE:
Reducing cardiovascular mortality in chronic kidney disease: something borrowed, something new

AUTHOR CONTACT:
Darryl Quarles
University of Tennessee Health Science Center, memphis, TN, USA
Phone: 901-448-1459; Fax: 901-448-1188; E-mail: dquarles@uthsc.edu

View this article at: http://www.jci.org/articles/view/67203?key=054ae63743c930253936


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related biology technology :

1. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
2. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
3. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
4. Emerging Lymphoma and Myeloma Treatments Focus on Improving Individual Patient Response
5. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
6. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
7. SFJ Pharma Ltd. II, Announces Agreement With Pfizer to Develop Axitinib for Adjuvant Treatment of Renal Cell Carcinoma
8. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
9. LoneStar Heart Acquires Worldwide Exclusive Rights to New Class of Small Molecules That May Lead to New Treatments for Diabetes
10. Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7)
11. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... , April 15, 2016  A new partnership ... more accurate underwriting decisions in a fraction of ... competitively priced and high-value life insurance policies to ... With Force Diagnostics, rapid testing (A1C, ... data readings (blood pressure, weight, pulse, BMI, and ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
Breaking Biology News(10 mins):